Eladocagene Exuparvovec-tneq (Kebilidi) coverage
Customize your policy alerts
Sign up for Ambetter Georgia Policy CP.PHAR.595 alerts
Get alerted when Policy CP.PHAR.595 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization requirements for Kebilidi gene therapy for AADC deficiency for Ambetter Georgia lines of business (Commercial, HIM, Medicaid). Applies to providers requesting coverage for the drug.
Reduced the age requirement to 16 months to align with product labeling and pivotal study minimum age; added requirement for documentation that the member has achieved skull maturity by neuroimaging; updated FDA maximum dose and dosing regimen; added disclaimer that all requests require medical director review.
Revised initial criteria to clarify anti-AAV2 neutralizing antibody titer 'does not exceed > 1,200 fold.'
Restricted Kebilidi to age < 11 years and to members who are unable to ambulate independently with or without assistive device based on available evidence.
Added redirect of prior authorization reviews to Precision Drug Action Committee (PDAC) Utilization Management Review.
Coverage Criteria
Initial Therapy
Covered when ALL of the following are met for AADC deficiency (Initial Approval):
See Appendix E for details on tests
See Appendix D for symptom details
Contraindication if not achieved
Administer as four 0.08 mL intraputaminal infusions per dosing guidance
Initial Therapy / Coverage Preconditions
Coverage and authorization are contingent on meeting FDA-aligned labeling criteria and additional utilization management requirements.
1Q2026 review added restriction to age <11 years and requirement that member is unable to ambulate independently in available evidence contexts; all requests require medical director review and some are redirected to PDAC Utilization Management Review.
Non‑FDA approved indications that are not specifically addressed in this policy are not authorized for coverage unless the request is supported under the Health Plan's applicable off‑label use policies. Coverage and authorization are contingent on meeting the policy's FDA‑aligned labeling criteria and utilization management requirements, including documented diagnostic confirmation and required prior authorization review.
A defined contraindication for eladocagene exuparvovec‑tneq is when the member has not achieved skull maturity as assessed by neuroimaging. Requests for members without documented skull maturity should be denied per the contraindication.
This policy was revised following utilization review to restrict use to members under age 11 and to those who are unable to ambulate independently (with or without assistive device) based on the available evidence. These restrictions function as exclusionary limits beyond the original FDA minimum age criterion and must be met for authorization.
Current evidence does not support the medical necessity of Kebilidi for members who are ≥ 11 years of age or for members who are ambulatory. The policy notes absence of efficacy data for these populations and therefore considers treatment not medically necessary for these groups.
Requests that do not meet the updated, labeling‑aligned criteria — including requirements for age (minimum 16 months and where applicable <11 years), documented skull maturity by neuroimaging, and baseline anti‑AAV2 neutralizing antibody titers within the clarified threshold — or that lack the required supporting documentation will be subject to the Health Plan's review process and may be denied or redirected to the Precision Drug Action Committee (PDAC) Utilization Management Review.
Initial Therapy Criteria and Dosing
Initial dosing
Initial therapy dosing and administration
See section V for administration details
Single-dose vial extractable volume and administration details in DOSAGE AND ADMINISTRATION section
Initial Therapy
Initial therapy coverage aligned to FDA labeling with additional utilization review requirements.
All requests require medical director review and may be redirected to the Precision Drug Action Committee (PDAC) Utilization Management Review.
Continuation Therapy Criteria
Continuation Therapy
Continued therapy policy
Approval duration not applicable
Coding and Billing
Provider Actions and Requirements
Prior authorization required
Prior authorization is required for all requests for Kebilidi; submit a prior authorization request with supporting clinical documentation demonstrating all approval criteria are met. All requests reviewed under this policy require Precision Drug Action Committee (PDAC) Utilization Management Review (see CC.PHAR.21) and medical director review as noted in the policy.
PDAC routing and medical director review
Prior authorization reviews are routed to the Precision Drug Action Committee (PDAC) Utilization Management Review and require medical director review per the policy; expect PDAC-level utilization review for adjudication.
- Refer to CC.PHAR.21 for PDAC process details.
No continuation therapy (one-time dose only)
No continuation or repeat dosing will be authorized — Kebilidi is dosed one time only and continued therapy is not authorized.
- Authorization duration is recorded as 3 months for the one-time dose.
Removal of prior redirection to symptomatic therapies
Earlier policy language redirecting candidates to symptomatic relief therapies was removed when criteria were aligned to FDA labeling; do not expect step-therapy redirection to symptomatic-only treatments.
- The removal was part of the update aligning criteria to FDA product labeling and dosing.
Submit supporting clinical documentation
Provider must submit complete supporting documentation (office notes, lab results, imaging, and other clinical information) demonstrating the member meets all initial approval criteria.
- Documentation should show prescriber specialty (geneticist or neurologist) and details of clinical symptoms.
- Include records of prior therapies and confirmation that member has not received prior gene therapy.
Provide diagnostic confirmation (two positive tests)
Diagnostic evidence must include positive results from two of the core diagnostic tests for AADC deficiency: CSF neurotransmitter metabolite panel, single gene/genetic panel testing, or plasma AADC enzyme assay.
- Appendix E recommends performing all three tests when feasible; acceptable documentation includes laboratory reports or genetics results.
Include member age and skull maturity evidence
Documentation must include the member's age consistent with the policy and evidence of skull maturity by neuroimaging: the policy requires age ≥16 months and (per 1Q2026 revision) restricted to <11 years in applicable contexts, plus imaging that documents skull maturity.
- Provide date of birth or age calculation showing ≥16 months and, where applicable, <11 years per the 1Q2026 restriction.
- Attach neuroimaging reports that explicitly document skull maturity.
Denial risk for incomplete or non‑eligible cases
Requests that do not meet all initial approval criteria risk denial — common triggers include missing diagnostic confirmation, age outside the policy limits (≥16 months and in practice restricted to <11 years), prior receipt of gene therapy, skull immaturity, antibody titers above the specified threshold, or ambulatory status.
- Ensure documentation shows member is unable to ambulate independently; ambulatory patients are not supported by current evidence.
- Confirm no prior gene therapy is documented.
Denial risk: age, skull maturity, and antibody titers
Requests failing to meet the updated age/skull maturity or antibody titer requirements may be denied or routed to PDAC; specifically, lack of documentation that the member is <11 years where required, absence of neuroimaging evidence of skull maturity, or anti‑AAV2 neutralizing antibody titers exceeding the clarified threshold are denial triggers.
- Anti‑AAV2 neutralizing antibody titer must not exceed > 1,200 fold (ELISA OD > 1 also specified); include lab reports with numeric titer values.
- Provide neuroimaging reports showing skull maturity to avoid contraindication-based denial.
Site of Care
Hospital outpatient — intraputaminal infusion per dosing instructions
Intraputaminal infusion (surgical stereotactic intracranial infusion) must follow the dosing instructions: total dose 1.8×10^11 vg (0.32 mL) delivered as four 0.08 mL intraputaminal infusions at 0.003 mL/minute (27 minutes per site); single‑dose vial contains extractable volume for intraputaminal administration.
- Setting: hospital outpatient per site‑of‑care guidance.
Dosing updated to FDA labeling; site‑of‑care specifics limited
Policy and dosing have been updated to reflect FDA labeling; site‑of‑care specifics beyond hospital outpatient are not provided in this document fragment.
- Refer to the full policy and administration sections for complete site‑of‑care logistics and dosing details.
Quantity Limits
Background
Eladocagene exuparvovec‑tneq (Kebilidi) is a recombinant adeno‑associated virus serotype 2 (rAAV2)–based gene therapy that delivers the DDC gene to restore aromatic L‑amino acid decarboxylase (AADC) enzyme activity in patients with AADC deficiency. The therapy is administered as a one‑time intraputaminal (stereotactic intracranial) infusion to deliver a maximum total dose of 1.8×10^11 viral genomes (vg) (0.32 mL total volume) per the dosing regimen; baseline anti‑AAV2 neutralizing antibody testing and demonstration of skull maturity by neuroimaging are required prior to authorization. All requests require prior authorization and medical director review and may be redirected to the PDAC Utilization Management Review per policy updates.
Definitions
Step Therapy
| Step | Requirement / Description | Coverage |
|---|---|---|
| {"text":"1","status":""},{"text":"No step therapy sequence specified. Earlier language that redirected requests to symptomatic relief therapies was removed when criteria were aligned to FDA labeling; therapy is a one-time gene therapy and continued therapy will not be authorized.","status":""},{"text":"neutral","status":""} |
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.